Skystar Bio closes direct stock offering


Skystar Bio-Pharmaceutical Company (SKBI -6.3%) raises $5M in a direct offering of stock and warrants to an institutional investor. Under the terms of the agreement, the investor will purchase 790,514 shares of common stock at $5.06 per share and warrants to purchase up to 197,629 shares of common for an aggregate price of $4M plus 1,000 shares of convertible preferred stock and warrants to purchase 49,407 shares of common stock for an aggregate price of $1M.

The conversion price of the preferred stock is $5.06 and the exercise price of the warrants is $6.25. The warrants are exercisable six months following issuance and will expire 12 months from the initial exercise date.

Net proceeds will be used for acquisitions, licenses of new vaccine and aquaculture products, R&D and general corporate purposes.

Comments (1)
  • frog_belly1
    , contributor
    Comments (24) | Send Message
     
    SABBY capital. I bet Hal Mintz is pissed off big time.
    17 Dec 2015, 09:10 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs